2.12
price up icon6.00%   0.12
after-market 시간 외 거래: 2.10 -0.02 -0.94%
loading
전일 마감가:
$2.00
열려 있는:
$2
하루 거래량:
5.34M
Relative Volume:
1.53
시가총액:
$398.81M
수익:
$116.33M
순이익/손실:
$-209.25M
주가수익비율:
-0.7518
EPS:
-2.82
순현금흐름:
$-135.49M
1주 성능:
+1.92%
1개월 성능:
-1.85%
6개월 성능:
+1.92%
1년 성능:
+105.83%
1일 변동 폭
Value
$1.965
$2.14
1주일 범위
Value
$1.965
$2.195
52주 변동 폭
Value
$0.865
$3.40

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
명칭
Esperion Therapeutics Inc
Name
전화
734-887-3903
Name
주소
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
직원
240
Name
트위터
@esperioninc
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
ESPR's Discussions on Twitter

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-03-16 다운그레이드 BofA Securities Neutral → Underperform
2023-03-16 다운그레이드 Northland Capital Market Perform → Under Perform
2023-03-07 업그레이드 Credit Suisse Underperform → Neutral
2023-02-27 재개 BofA Securities Neutral
2023-02-24 업그레이드 Jefferies Hold → Buy
2023-02-03 업그레이드 Morgan Stanley Underweight → Equal-Weight
2022-08-03 다운그레이드 Credit Suisse Neutral → Underperform
2022-05-05 업그레이드 JP Morgan Underweight → Neutral
2022-03-10 개시 H.C. Wainwright Buy
2021-10-19 다운그레이드 Credit Suisse Outperform → Neutral
2021-10-14 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2021-05-05 다운그레이드 Stifel Buy → Hold
2021-04-26 재개 Credit Suisse Outperform
2021-03-11 개시 Morgan Stanley Equal-Weight
2021-02-12 다운그레이드 Jefferies Buy → Hold
2021-02-09 다운그레이드 Goldman Neutral → Sell
2021-01-15 다운그레이드 BofA Securities Buy → Neutral
2020-11-10 업그레이드 Credit Suisse Neutral → Outperform
2020-09-29 재개 JP Morgan Underweight
2020-08-11 다운그레이드 Credit Suisse Outperform → Neutral
2020-04-01 재개 BofA/Merrill Buy
2020-03-17 업그레이드 Citigroup Neutral → Buy
2020-02-24 다운그레이드 Northland Capital Outperform → Market Perform
2020-02-14 다운그레이드 Citigroup Buy → Neutral
2019-09-16 업그레이드 Goldman Sell → Neutral
2019-05-29 다운그레이드 Goldman Neutral → Sell
2019-05-06 업그레이드 BofA/Merrill Underperform → Neutral
2019-04-26 업그레이드 Goldman Sell → Neutral
2019-03-13 업그레이드 JP Morgan Underweight → Neutral
2019-01-07 재확인 Needham Strong Buy
2018-12-13 개시 Goldman Sell
2018-10-29 업그레이드 Northland Capital Market Perform → Outperform
2018-10-16 개시 BTIG Research Buy
2018-08-17 업그레이드 Citigroup Neutral → Buy
2018-07-11 다운그레이드 Northland Capital Outperform → Market Perform
2018-05-03 다운그레이드 JP Morgan Neutral → Underweight
2018-05-02 다운그레이드 BofA/Merrill Buy → Underperform
모두보기

Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스

pulisher
02:54 AM

Vanguard Group Inc's Strategic Acquisition in Esperion Therapeutics Inc - GuruFocus.com

02:54 AM
pulisher
Nov 04, 2024

Esperion to Participate in Upcoming Jefferies London Healthcare Conference - GlobeNewswire

Nov 04, 2024
pulisher
Oct 31, 2024

Esperion Announces a Featured Presentation in the Late - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three - The Bakersfield Californian

Oct 31, 2024
pulisher
Oct 31, 2024

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Esperion Therapeutics (ESPR) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy - MarketBeat

Oct 26, 2024
pulisher
Oct 24, 2024

Esperion to Report Third Quarter 2024 Financial Results on November 7 - GlobeNewswire

Oct 24, 2024
pulisher
Oct 24, 2024

ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 24, 2024
pulisher
Oct 23, 2024

Nexletol From Esperion - Pharmacy Times

Oct 23, 2024
pulisher
Oct 18, 2024

Esperion Therapeutics' chief commercial officer sells shares worth $226 - Investing.com

Oct 18, 2024
pulisher
Oct 18, 2024

Esperion Therapeutics' chief commercial officer sells shares worth $226 By Investing.com - Investing.com UK

Oct 18, 2024
pulisher
Oct 17, 2024

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance

Oct 17, 2024
pulisher
Oct 11, 2024

Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Zacks Research - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR) - MarketBeat

Oct 10, 2024
pulisher
Oct 05, 2024

Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Cut by Analyst - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Esperion shares reiterate Buy rating on trial data By Investing.com - Investing.com South Africa

Oct 03, 2024
pulisher
Oct 03, 2024

Esperion shares reiterate Buy rating on trial data - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5? - Insider Monkey

Oct 03, 2024
pulisher
Oct 02, 2024

Esperion reports LDL-C reduction success in MILOS study By Investing.com - Investing.com South Africa

Oct 02, 2024
pulisher
Oct 02, 2024

Esperion reports LDL-C reduction success in MILOS study - Investing.com

Oct 02, 2024
pulisher
Oct 02, 2024

Esperion Therapeutics' (ESPR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid - The Manila Times

Oct 02, 2024
pulisher
Oct 02, 2024

Esperion EU Partner Reports Final Real-World Results from - GlobeNewswire

Oct 02, 2024
pulisher
Sep 30, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Large Decline in Short Interest - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Marshall Wace LLP Raises Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

7 Best NASDAQ Stocks Under $5 - Insider Monkey

Sep 30, 2024
pulisher
Sep 27, 2024

Esperion Therapeutics (NASDAQ:ESPR) Lowered to Hold at StockNews.com - MarketBeat

Sep 27, 2024
pulisher
Sep 25, 2024

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Taking a Closer Look At Esperion Therapeutics Inc. (ESPR) Following Its Recent Trade - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

ESH Acquisition Corp. (NASDAQ:ESHA) Shares Bought by Berkley W R Corp - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

What's Going On With Seelos Therapeutics Stock Tuesday? - Benzinga

Sep 24, 2024
pulisher
Sep 24, 2024

Great Point Partners LLC Sells 2,208,406 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

ESAB Co. (NYSE:ESAB) Stock Position Cut by Front Street Capital Management Inc. - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug - XM

Sep 24, 2024
pulisher
Sep 24, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Sold by Great Point Partners LLC - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

New Pill Cuts Cholesterol and Heart Attacks - Greek Reporter

Sep 24, 2024
pulisher
Sep 23, 2024

What to expect from Esperion Therapeutics Inc.’s (ESPR) current quarter earnings? - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Atopic dermatitis: New drug significantly improves symptoms - Medical News Today

Sep 23, 2024
pulisher
Sep 23, 2024

How does ESAB Corp (ESAB) change from a tortoise to a hare? - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Raised by XTX Topco Ltd - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

XTX Topco Ltd Has $810,000 Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Espey Mfg. & Electronics (NYSEAMERICAN:ESP) Receives New Coverage from Analysts at StockNews.com - Defense World

Sep 23, 2024
pulisher
Sep 21, 2024

Inspire Investing LLC Invests $758,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Sep 21, 2024
pulisher
Sep 20, 2024

ESAB Co. (NYSE:ESAB) Shares Sold by Granite Investment Partners LLC - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Bank of New York Mellon Corp Acquires 555,382 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

18,727 Shares in ESAB Co. (NYSE:ESAB) Bought by Seven Eight Capital LP - Defense World

Sep 19, 2024

Esperion Therapeutics Inc (ESPR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$12.67
price up icon 0.88%
$114.96
price down icon 0.42%
$89.24
price up icon 3.56%
$58.48
price down icon 0.36%
$121.53
price up icon 0.83%
$11.61
price up icon 1.40%
자본화:     |  볼륨(24시간):